GSK gets European marketing rights for Nucala to treat asthma

UK drug major GlaxoSmithKline (LSE: GSK) said the European Commission has granted marketing rights for its drug Nucala (mepolizumab) as an add-on treatment for asthma.

Nucala is now approved for use in the 31 European countries covered by the European Medicines Agency (EMA), following the go ahead from the European Commission.

Eric Dube, head of GSK Global Respiratory Franchise, said: “The marketing authorization of Nucala in the EU is a significant treatment advance for appropriate asthma patients and reinforces GSK’s leadership in respiratory. We are proud that our work in this area, to better understand the specific role eosinophils play in severe asthma, has resulted in the licensing of mepolizumab as the first anti-IL-5 biological treatment. We aim to offer this medicine to patients as soon as possible.”